Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2006-03-22 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Aridol approved by TGA 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 23 March 2006 announcing the approval of Pharmaxis' first product, Aridol, by the Therapeutic Goods Administration (TGA) in Australia. It is a press release describing a regulatory milestone and commercial launch plans, not a financial report or detailed regulatory filing. There are no financial statements, management discussion, or detailed regulatory disclosures. The document is promotional and informational about product approval and company background. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like Annual Report, Earnings Release, or Capital Update.
2006-03-22 English
Updated Investor Presentation 33 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing forward-looking statements, descriptions of products in development, clinical trial phases, regulatory status updates, marketing plans, and management team bios. It references filings with the US Securities and Exchange Commission and includes extensive information about the company's strategy, product pipeline, and market opportunities. The presence of slides, images, and structured content typical of investor communications further supports this. There is no indication that this is a formal regulatory filing like an annual or quarterly report, audit report, or legal proceeding. It is not a transcript of a call or a voting result announcement. The document is clearly an investor-focused presentation providing detailed financial and strategic information to stakeholders. Therefore, the most appropriate classification is Investor Presentation (IP). The document length and content confirm it is the full presentation, not just an announcement or summary.
2006-03-20 English
Final Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act, which relate to disclosures of directors' shareholdings and interests. The content details the director's relevant interests in securities, including ordinary shares and options, and notes the director ceased to be a director on a specific date. There is no financial performance data, earnings information, or report content. This matches the definition of Director's Dealing filings, which report personal share transactions or holdings by company directors and executives (insider trades). The document length is short and focused solely on director interests, confirming it is not a full report or announcement of a report. Therefore, the correct classification is Director's Dealing (DIRS).
2006-03-20 English
Initial Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X' and references ASX listing rule 3.19A.1, which pertains to disclosures of directors' interests in securities. It details the initial director's interest notice for Dr Peter C Farrell, including securities held and relevant contracts. There is no financial data, report, or analysis present. The content is a report of personal share transactions or holdings by a company director, fitting the definition of Director's Dealing filings.
2006-03-20 English
Majority of Pharmaxis Board Now Independent 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a media release dated 20 March 2006 from Pharmaxis Ltd announcing that the majority of its board is now independent following a director stepping down. It discusses board composition and governance principles but does not contain financial statements, detailed financial performance, or substantive financial data. The document is relatively short (3523 characters) and serves as an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is clearly about board composition changes, which aligns with Board/Management Information filings. Therefore, the document is best classified as Board/Management Information (MANG). Confidence is high given the clear content focus on board changes and the absence of financial data or other report types.
2006-03-19 English
Director Appointment 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a media release dated 16 March 2006 announcing that Dr. Peter Farrell has joined the board of Pharmaxis Ltd. It includes biographical information about Dr. Farrell, quotes from the CEO and Dr. Farrell, and general company background. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no legal proceedings, and no mention of any report being attached or published. The content focuses on a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4244 characters, which is consistent with a typical announcement rather than a full report or transcript. Confidence is high given the clear subject matter and format.
2006-03-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.